E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter

About 50–70% of breast cancers are estrogen receptor α (ERα) positive and most of them are sensitive to endocrine therapy including tamoxifen. However, one third of these patients will eventually develop resistance and relapse. We found that the expression of miR-15a and miR-16 were significantly de...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncotarget
Hoofdauteurs: Chu, Junjun, Zhu, Yinghua, Liu, Yujie, Sun, Lijuan, Lv, Xiaobin, Wu, Yanqin, Hu, Pengnan, Su, Fengxi, Gong, Chang, Song, Erwei, Liu, Bodu, Liu, Qiang
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Impact Journals LLC 2015
Onderwerpen:
Research Paper
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741652/
https://ncbi.nlm.nih.gov/pubmed/26397135
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items